A helix-PXXP-helix peptide with antibacterial activity without cytotoxicity against MDRPA-infected mice

Biomaterials

Volumn 35, Issue 3, 2014, Pages 1025-1039

  Lee, Jong Kook ^a   Park, Seong Cheol ^a   Hahm, Kyung Soo ^a,b   Park, Yoonkyung ^a  

^a Chosun University   (South Korea)

^b Bioleaders Corporation   (South Korea)

Author keywords

Antibiotic drug; Antimicrobial peptide; Helix PXXP helix motif; HPA3P2; Multidrug resistant clinical isolated P.aeruginosa; Septic shock mice

Indexed keywords

ANTIBIOTIC DRUGS; ANTIMICROBIAL PEPTIDE; HELIX-PXXP-HELIX MOTIF; HPA3P2; P.AERUGINOSA; SEPTIC SHOCKS;

AMINO ACIDS; ANTIBIOTICS; BACTERIA; BIOACTIVITY; CELL MEMBRANES; CYTOLOGY; MAMMALS; NUCLEIC ACIDS; POLYPEPTIDES;

CYTOTOXICITY;

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GLUTAMIC ACID; HPA3 PEPTIDE; HPA3P PEPTIDE; HPA3P2 PEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHENYLALANINE; POLYPEPTIDE ANTIBIOTIC AGENT; PROLINE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS SUBTILIS; BACTERIAL MEMBRANE; BINDING AFFINITY; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL STRUCTURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG EFFICACY; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; HELIX PXXP HELIX STRUCTURE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER INJURY; LOW DRUG DOSE; LUNG INJURY; MEMBRANE DAMAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECONDARY STRUCTURE; PSEUDOMONAS AERUGINOSA; RNA BINDING; SEPTIC SHOCK; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI; MUS; PSEUDOMONAS AERUGINOSA;

ANTIBIOTIC DRUG; ANTIMICROBIAL PEPTIDE; HELIX-PXXP-HELIX MOTIF; HPA3P2; MULTIDRUG-RESISTANT CLINICAL ISOLATED P. AERUGINOSA; SEPTIC SHOCK MICE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; CELL LINE; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELICOBACTER PYLORI; HEMOLYSIS; HUMANS; MICE; MICE, INBRED ICR; PROTEIN STRUCTURE, SECONDARY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RIBOSOMAL PROTEINS;

EID: 84887620253     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.10.035     Document Type: Article

References (48)

1. Peters B.M., Shirtliff M.E., Jabra-Rizk M.A. Antimicrobial peptides: primeval molecules or future drugs?. PLoS Pathog 2010, 28:e1001067.
2. Pompilio A., Crocetta V., Scocchi M., Pomponio S., Di Vincenzo V., Mardirossian M., et al. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol 2012, 12:145.
3. Lopes S.P., Ceri H., Azevedo N.F., Pereira M.O. Antibiotic resistance of mixed biofilms in cystic fibrosis: impact of emerging microorganisms on treatment of infection. Int J Antimicrob Agents 2012, 40:260-263.
4. Lech M., Römmele C., Kulkarni O.P., Susanti H.E., Migliorini A., Garlanda C., et al. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS One 2011, 6:e20118.
5. van Zoelen M.A., Verstege M.I., Draing C., de Beer R., van't Veer C., Florquin S., et al. Endogenous MCP-1 promotes lung inflammation induced by LPS and LTA. Mol Immunol 2011, 48:1468-1476.
6. Mangoni M.L., Shai Y. Temporins and their synergism against Gram-negative bacteria and in lipopolysaccharide detoxification. Biochim Biophys Acta 2009, 1788:1610-1619.
7. Wimley W.C., Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. JMembr Biol 2011, 239:27-34.
8. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol 2005, 3:238-250.
9. Yeaman M.R., Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003, 55:27-55.
10. Hancock R.E., Scott M.G. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A 2000, 97:8856-8861.
11. Scott M.G., Gold M.R., Hancock R.E. Interaction of cationic peptides with lipoteichoic acid and gram-positive bacteria. Infect Immun 1999, 67:6445-6453.
12. Gutsmann T., Hagge S.O., David A., Roes S., Böhling A., Hammer M.U., et al. Lipid-mediated resistance of Gram-negative bacteria against various pore-forming antimicrobial peptides. JEndotoxin Res 2005, 3:167-173.
13. Gee K., Kozlowski M., Kumar A. Tumor necrosis factor-alpha induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic cells. JBiol Chem 2003, 278:37275-37287.
14. Freudenberg M.A., Tchaptchet S., Keck S., Fejer G., Huber M., Schütze N., et al. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity. Immunobiology 2008, 213:193-203.
15. Glaser L. Bacterial cell surface polysaccharides. Annu Rev Biochem 1973, 42:91-112.
16. Di Guilmi A.M., Dessen A., Dideberg O., Vernet T. Bifunctional penicillin-binding proteins: focus on the glycosyltransferase domain and its specific inhibitor moenomycin. Curr Pharm Biotechnol 2002, 2:63-75.
17. Wilke M.S., Lovering A.L., Strynadka N.C. Beta-lactam antibiotic resistance: a current structural perspective. Curr Opin Microbiol 2005, 5:525-533.
18. Mereuta L., Luchian T., Park Y., Hahm K.S. The role played by lipids unsaturation upon the membrane interaction of the Helicobacter pylori HP(2-20) antimicrobial peptide analogue HPA3. JBioenerg Biomembr 2009, 1:79-84.
19. Pütsep K., Brändén C.I., Boman H.G., Normark S. Antibacterial peptide from H.pylori. Nature 1999, 398:671-672.
20. Lee D.G., Kim H.N., Park Y., Kim H.K., Choi B.H., Choi C.H., et al. Design of novel analogue peptides with potent antibiotic activity without hemolytic activity based on the antimicrobial peptide derived from N-terminal sequence of Helicobacter pylori ribosomal protein L1. Biochim Biophys Acta 2002, 1598:185-194.
21. Lee J.K., Gopal R., Park S.C., Ko H.S., Kim Y., Hahm K.S., et al. Aproline-hinge alters the characteristics of the amphipathic α-helical AMPs. PLoS One 2013, 8(7):e67597.
22. Scocchi M., Tossi A., Gennaro R. Proline-rich antimicrobial peptides: converging to a non-lytic mechanism of action. Cell Mol Life Sci 2011, 13:2317-2330.
23. Rapaport D., Shai Y. Aggregation and organization of pardaxin in phospholipid membranes. A fluorescence energy transfer study. JBiol Chem 1992, 10:6502-6509.
24. Nakao S., Komagoe K., Inoue T., Katsu T. Comparative study of the membrane-permeabilizing activities of mastoparans and related histamine-releasing agents in bacteria, erythrocytes, and mast cells. Biochim Biophys Acta 2011, 1:490-497.
25. Park S.C., Lee J.R., Shin S.O., Park Y., Lee S.Y., Hahm K.S. Characterization of a heat-stable protein with antimicrobial activity from Arabidopsis thaliana. Biochem Biophys Res Commun 2007, 3:562-567.
26. Mignon A., Rouquet N., Fabre M., Martin S., Pagès J.C., Dhainaut J.F., et al. LPS challenge in d-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Am J Respir Crit Care Med 1999, 159:1308-1315.
27. Soon R.L., Velkov T., Chiu F., Thompson P.E., Kancharla R., Roberts K., et al. Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxin-lipopolysaccharide binding interactions. Anal Biochem 2001, 2:273-283.
28. Sass V., Pag U., Tossi A., Bierbaum G., Sahl H.G. Mode of action of human beta-defensin 3 against Staphylococcus aureus and transcriptional analysis of responses to defensin challenge. Int J Med Microbiol 2008, 298:619-633.
29. Park S.C., Kim J.Y., Shin S.O., Jeong C.Y., Kim M.H., Shin S.Y., et al. Investigation of toroidal pore and oligomerization by melittin using transmission electron microscopy. Biochem Biophys Res Commun 2006, 1:222-228.
30. Choi S., Choi H.H., Lee S.H., Ko S.H., You H.J., Ye S.K., et al. Anti-inflammatory effects of 8-hydroxy-2'-deoxyguanosine on lipopolysaccharide-induced inflammation via Rac suppression in Balb/c mice. Free Radic Biol Med 2007, 12:1594-1603.
31. Hsu C.H., Chen C., Jou M.L., Lee A.Y., Lin Y.C., Yu Y.P., et al. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res 2005, 13:4053-4064.
32. Rosenfeld Y., Papo N., Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. JBiol Chem 2006, 3:1636-1643.
33. Wen Z., Liu Y., Li F., Wen T. Low dose of carbon monoxide intraperitoneal injection provides potent protection against GalN/LPS-induced acute liver injury in mice. JAppl Toxicol 2012, 10:2806.
34. Jeong N., Kim J.Y., Park S.C., Lee J.K., Gopal R., Yoo S., et al. Antibiotic and synergistic effect of Leu-Lys rich peptide against antibiotic resistant microorganisms isolated from patients with cholelithiasis. Biochem Biophys Res Commun 2010, 4:581-586.
35. Park S.C., Kim J.Y., Lee J.K., Hwang I., Cheong H., Nah J.W., et al. Antifungal mechanism of a novel antifungal protein from pumpkin rinds against various fungal pathogens. JAgric Food Chem 2009, 19:9299-9304.
36. Cho J.H., Sung B.H., Kim S.C. Buforins: histone H2A-derived antimicrobial peptides from toad stomach. Biochim Biophys Acta 2009, 1788:1564-1569.
37. Pandey B.K., Ahmad A., Asthana N., Azmi S., Srivastava R.M., Srivastava S., et al. Cell-selective lysis by novel analogues of melittin against human red blood cells and Escherichia coli. Biochemistry 2010, 49:7920-7929.
38. Harwig S.L., Ganz T., Lehrer R.I. Neutrophil defensins: purification, characterization and antimicrobial testing. Methods Enzymol 1994, 236:161-172.
39. Hirakata Y., Kaku M., Tomono K., Tateda K., Furuya M., Matsumoto T., et al. Efficiency of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice. Antimicrob Agents Chemother 1992, 36:1198-1203.
40. Kovach M.A., Ballinger M.N., Newstead M.W., Zeng X., Bhan U., Yu F.S., et al. Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia. JImmunol 2012, 189(1):304-311.
41. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
42. Ellman G.L. Tissue sulfhydryl group. Arch Biochem Biophys 1959, 82:70-77.
43. Yoshikawa T., Yokoe N., Takemura S., Kato H., Hotta T., Matsumura N., et al. Lipid peroxidation and lysosomal enzymes in d-galactosamine hepatitis and its protection by vitamin E. Gastroenterol Jap 1979, 14:31-39.
44. Park S.C., Kim M.H., Hossain M.A., Shin S.Y., Kim Y., Stella L., et al. Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions. Biochim Biophys Acta 2008, 1778(1):229-241.
45. Farnaud S., Spiller C., Moriarty L.C., Patel A., Gant V., Odell E.W., et al. Interactions of lactoferricin-derived peptides with LPS and antimicrobial activity. FEMS Microbiol Lett 2004, 233:193-199.
46. Rosenfeld Y., Sahl H.G., Shai Y. Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry 2008, 47:6468-6478.
47. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. NEngl J Med 2003, 348:1546-1554.
48. Fritsche S., Knappe D., Berthold N., von Buttlar H., Hoffmann R., Alber G. Absence of invitro innate immunomodulation by insect-derived short proline-rich antimicrobial peptides points to direct antibacterial action invivo. JPept Sci 2012, 10:599-608.